## CORRECTED **VERSION\***





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)		
(51) International Patent Classification <sup>6</sup> :  C12N 15/12, C07K 14/47, C12N 15/11, A61K 38/17, 31/70, C12Q 1/68, G01N	A2	(11) International Publication Number: WO 99/36536 (43) International Publication Date: 22 July 1999 (22.07.99)
33/68, A61K 48/00  (21) International Application Number: PCT/US99/01087  (22) International Filing Date: 19 January 1999 (19.01.99)		CH, CY, DE, DK, ES, PI, PK, OB, GM
(30) Priority Data: 60/071,950 20 January 1998 (20.01.98)	,	Published  Without international search report and to be republished upon receipt of that report.
(71) Applicant (for all designated States except US): BLO	OD CI	N-

(71) Applicant (for all designated State TER RESEARCH FOUNDATION [US/US]; 638 North 18th Street, P.O. Box 2178, Milwaukee, WI 53233 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): SIMS, Peter, J. [US/US]; 13386 Caminito Mar Villa, Del Mar, CA 92014 (US). WIEDMER, Therese [US/US]; 13386 Caminito Mar Villa, Del Mar, CA 92014 (US). ZHAO, Ji [US/US]; Apartment 105, 309 North Solano Hills Drive, Solano, CA 92075 (US).
- (74) Agent: BAKER, Jean, C.; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).

(54) Title: METHODS AND COMPOSITIONS TO ALTER TISSUE SUSCEPTIBILITY TO IMMUNE INJURY, TO PROGRAMMED CELL DEATH, AND TO CLEARANCE BY THE RETICULOENDOTHELIAL SYSTEM

## (57) Abstract

A method for extending the viability of mammalian cells or tissues comprising the step of inhibiting the expression of native PL scramblase within the cell or tissue is disclosed. In another embodiment of the invention, a method of decreasing the viability, metastatic or invasive potential of cancer cells, cancerous tissue, or viralinfected cell by causing increased expression or activity of PL scramblase protein within the cell or tissue is disclosed.

50 40 MEAPRSGTYLPAGYAPQYPPAAVQGPPEHTGRPTFQTNYQVPQSGYPGPQASY MUR MDKQNSQMNASHPETNLPVGYPPQYPPTAFQGPPGYSGYPGPQVSYPPPPAGHSGPGPA-HUM 50 30 10 100 90 80

TVSTSGHEGYAATRLPIQNNQTIVLANTQWMPAPPPILNCPPGLEYLNQIDQLLIHQQVE -PV-YNQPVGAAGVPWMPAPQPPLNCPPGLEYLSQIDQILIHQQIE . .... :.. GFPVPNQPVYNQ--80 70 60

140 LLEVLTGFETNNKFEIKNSLGQMVYVAVEDTDCCTRNCCEASRPFTLRILDHLGQEVMTL 130 LLEVITGFETNNKYEIKNSFGQRVYFAAEDTDCCTRNCCGPSRPFTLRIIDNMGQEVITL MUR 150 140 130 120

A

220 200 210 ERPLRCSSCCFPCCLQEIEIQAPPGVPIGYVTQTWHPCLPKLTLQNDKRENVLKVVGPCV 190 ERPLRCSSCCCPCCLQEIEIQAPPGVPIGYVIQTWHPCLPKFTIQNEKREDVLKISGPCV HUM 210 220 200 180

260 270 ACTCCSDIDFEIKSLDEVTRIGKITKOWSGCVKEAFTDSDNFGIQFPLDLEVKMKAVTLG 250 MUR VCSCCGDVDFEIKSLDEQCVVGKISKHWTGILREAFTDADNFGIQFFLDLDVKMKAVMIG HUM 260 240

ACFLIDYMFFEGCE 1::::::: <u>ACFLIDEMFFESTG</u>SQEQKSGVW

В

<sup>\*(</sup>Referred to in PCT Gazette No. 44/1999, Section II)